Methodological considerations for interpreting ketamine-naltrexone trials in depression
Igor D. Bandeira, Luke A. Jelen, Jason M Tucciarone, Boris D. Heifets, Carolyn I. Rodríguez, Alan F. Schatzberg
The International Journal of Neuropsychopharmacology October 1, 2025 DOI: 10.1093/ijnp/pyaf073 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Depression Esketamine Ketamine |
| Keywords | Depression economics Medline Clinical trial Clinical neurology Clinical psychology |
| Citations | 4 |
| Key findings | Argues that ketamine and esketamine show rapid antidepressant effects but that long-term safety and optimal treatment protocols require further investigation. |
Abstract
Igor D Bandeira, MD, PhD, Luke A Jelen, MD, PhD, Jason M Tucciarone, MD, PhD, Boris D Heifets, MD, PhD, Carolyn I Rodriguez, MD, PhD, Alan F Schatzberg, MD
Comparable studies
Other narrative reviews on ketamine for depression, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation Adults with treatment-resistant depression | 2021 | Review | |
| Ketamine: a paradigm shift for depression research and treatment | 2019 | Review | |
| Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective | 2019 | Review | |
| Ketamine: A tale of two enantiomers | 2020 | Review | |
| Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor | 2021 | Review |